SNTI (Senti Biosciences Holdings) Tariff Resilience Score: 6/10 (As of Jul. 12, 2026)


SNTI Senti Biosciences Holdings Inc SNTI
22 GF Score
Price $1.03
! 7 Warning Signs
View Full Analysis

What is Senti Biosciences Holdings Tariff Resilience Score?

Senti Biosciences Holdings SNTI +3.00% 22 Tariff Resilience Score is 6 as of Jul. 12, 2026. GuruFocus rates SNTI with a GF Score™ of 22/100. The stock has 7 warning signs investors should review. Among 1,370 Biotechnology companies, Senti Biosciences Holdings ranks better than 75.99% on this metric.

Senti Biosciences Holdings has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Senti Biosciences Holdings has Senti Biosciences Inc benefits from a strong domestic market focus and minimal reliance on international supply chains. While some components are imported, the company has alternative suppliers and moderate pricing power to mitigate tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Senti Biosciences Holdings might have Average Resilient.

Senti Biosciences Holdings  (NAS:SNTI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Senti Biosciences Holdings Tariff Resilience Score Related Terms

SNTI vs ALGS, CRVO, NTRB: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Senti Biosciences Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senti Biosciences Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Senti Biosciences Holdings's Tariff Resilience Score falls into.


SNTI
22GF Score
Senti Biosciences Holdings Inc SNTI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Senti Biosciences Holdings (SNTI) has a Tariff Resilience Score of 6 as of Jul. 12, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Senti Biosciences Holdings ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Senti Biosciences Holdings' Tariff Resilience Score too high?
Senti Biosciences Holdings' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Senti Biosciences Holdings' value of 6 is 50% above this industry median. Based on the distribution chart, Senti Biosciences Holdings ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Senti Biosciences Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' Tariff Resilience Score compare to ALGS and CRVO?
According to the Biotechnology industry distribution chart, Senti Biosciences Holdings ranks #329 out of 1370 companies for Tariff Resilience Score. This places Senti Biosciences Holdings in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Senti Biosciences Holdings' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senti Biosciences Holdings's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senti Biosciences Holdings's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Senti Biosciences Holdings' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current Tariff Resilience Score is 6 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senti Biosciences Holdings Business Description

Address 2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
22GF Score

Get the complete analysis for SNTI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price